搜索
 > 【Fas】重组蛋白信息

Fas信息

英文名称:Apoptosis-mediating surface antigen FAS
中文名称:Fas抗原
靶点别称:FASLG receptor,Apo-1 antigen,Apoptosis-mediating surface antigen FAS,APT1,Apoptosis antigen 1,CD95,TNFRSF6,FAS1,FAS
上市药物数量:0
临床药物数量:3
最高研发阶段:临床二期

Fas产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
FAS-H5229
Human
Human Fas / TNFRSF6 / CD95 Protein, His Tag
FAS-H5252
Human
Human-Fas-CD95-Protein-C-Fc Tag

Fas 分子别名

FAS,ALPS1A,APO1,APT1,CD95,FAS1,FASTM,TNFRSF6,FasR

Fas 分子背景

The Fas is also known as FAS receptor (FasR), apoptosis antigen 1 (APO-1 or APT), cluster of differentiation 95 (CD95) or tumor necrosis factor receptor superfamily member 6 (TNFRSF6). is a death receptor on the surface of cells that leads to programmed cell death (apoptosis). It is one of two apoptosis pathways, the other being the mitochondrial pathway. FasR is located on chromosome 10 in humans and 19 in mice. Similar sequences related by evolution (orthologs) are found in most mammals. Fas forms the death-inducing signaling complex (DISC) upon ligand binding. Membrane-anchored Fas ligand trimer on the surface of an adjacent cell causes trimerization of Fas receptor. This event is also mimicked by binding of an agonistic Fas antibody, though some evidence suggests that the apoptotic signal induced by the antibody is unreliable in the study of Fas signaling. To this end, several clever ways of trimerizing the antibody for in vitro research have been employed.Upon ensuing death domain (DD) aggregation, the receptor complex is internalized via the cellular endosomal machinery. This allows the adaptor molecule FADD to bind the death domain of Fas through its own death domain. Recently, Fas has also been shown to promote tumor growth, since during tumor progression, it is frequently downregulated or cells are rendered apoptosis resistant. Cancer cells in general, regardless of their Fas apoptosis sensitivity, depend on constitutive activity of Fas. This is stimulated by cancer-produced Fas ligand for optimal growth.

Fas 参考文献

Fas临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
APO-010 APO-010 临床二期 Onxeo SA, Oncology Venture 实体瘤, 多发性骨髓瘤 详情
Anti-APO-1 monoclonal antibody DE-098; ARG-098 临床二期 Centocor, 强生, 参天, Argenes 类风湿性关节炎
CTLA-4/FasL fusion protein (KAHR Medical) KAHR-102 临床申请 KAHR Medical 淋巴瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定